BlueGnome Licenses Karyomapping IP in Bid to Bolster Pre-Implantation Genetic-Dx Play
October 19, 2010
BlueGnome Licenses Karyomapping IP in Bid to Bolster Pre-Implantation Genetic-Dx Play
Cambridge, UK-based BlueGnome made the acquisition to carve out a bigger piece of the pre-implantation, genetic-diagnostic market. The firm "aims to address diagnosis of single-gene disorders using SNP-array technology," according to its CEO.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.